About Contact Us Careers

Transient Elastography Devices Market Size & Share, by Technology (Vibration-Controlled TE (VCTE), Shear Wave Elastography (SWE)); Product Type, Application, End user - SWOT Analysis, Competitive Strategic Insights, Regional Trends 2026-2035

  • Report ID: 665
  • Published Date: Sep 29, 2025
  • Report Format: PDF, PPT

Transient Elastography Devices Market Outlook:

Transient Elastography Devices Market size was valued at USD 326.9 million in 2025 and is projected to reach USD 759.6 million by the end of 2035, rising at a CAGR of 8.8% during the forecast period 2026-2035. In 2026, the industry size of transient elastography devices is evaluated at USD 355.6 million.

The market is fueled by the rising prevalence of chronic liver diseases, including non-alcoholic fatty liver disease (NAFLD) and hepatitis B/C infections, around the world. In this regard, the WHO in April 2024 reported that 254 million people live with hepatitis B and 50 million with hepatitis C in 2022. Thus, several concerned authorities are investing heavily in this sector to increase public access to advanced diagnosis and treatment. For instance, in 2023, a screening program was released by the government of Europe, aiming to reduce liver fibrosis progression by the end of 2030, as per the European Association for the Study of the Liver.

The standard pricing structure in the market is highly stimulated by disruptions in the supply chain of raw materials and critical components. Testifying this, the International Trade Centre (ITC) reported that the major suppliers of such essentials, including ultrasound transducers, shear wave sensors, and AI-based processing units, were the U.S., Germany, and Japan. On the other hand, the global trade of medical instruments reached USD 167 billion, including the transient elastography devices. These dynamics demonstrate the device pricing changes in trade policies and geopolitics, which affects market accessibility and competitiveness globally.

Transient Elastography Devices Market Size
Discover Market Trends & Growth Opportunities: Request Free Sample PDF

Growth Drivers

  • Continuous investment in extensive R&D: The integration of advanced technologies, such as artificial intelligence (AI) and cloud computing, is revolutionizing the efficacy and utility of the products available in the market. This is pushing organizations to invest heavily in developing more efficient and multi-functional solutions. For instance, the global research, development, and deployment (RDD) fund allocation in this field was dedicated to AI-enhanced elastography. Furthermore, the growing focus on innovating tools for delivering multi-organ fibrosis assessment and user convenience is expanding the pipeline of this sector.
  • Rising liver disease prevalence: The global epidemic of non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) is the primary demand driver. The American Liver Foundation report in July 2025 estimates that NAFLD affects approximately 25% of the U.S. population. On the other hand, the WHO's global hepatitis elimination strategy necessitates a widespread of screening and monitoring, creating a massive, sustained patient pool requiring non-invasive fibrosis assessment and driving device adoption in both developed and emerging markets.
  • Major unmet demand in emerging markets: High adoption of advancements in technology in medical sector is mostly seen in developed economies. It is necessary for the regions such as Asia-Pacific and Latin America to persist in advancements. According to the July 2025 WHO data, nearly 75% of the people have chronic hepatitis B in the Asia-Pacific, with an estimated 254 million individuals worldwide suffering from chronic hepatitis B as of 2022. Sustained high rates of hepatitis B and C in these areas, combined with nascent screening programs, offer vast growth opportunities. Manufacturers with affordable solutions specific to these markets can seize this chance, with government efforts to enhance diagnostic facilities and address WHO elimination targets.

Global Trade Flow of Medical Instruments (Relevant to Transient Elastography Devices, 2023)

Country

Export Value (USD)

Import Value (USD)

U.S.

34.8B

37.7

Germany

18.4B

13.1

Mexico

17.6B

4.62

Netherlands

9.38

14.1B

Source: OEC 2023

Challenge

  • Economic disparities and financial exhaustions: Despite the government subsidies and reimbursement policy improvement, baseline affordability and high out-of-pocket costs are still a few of the major hurdles in the transient elastography devices sector. Particularly, in the regions with limited resources and budget-constrained healthcare systems, the available products become more expensive for a majority of individuals. In addition, the amplifying burden of financial exhaustion among payers may also impact the wide adoption in this field. However, innovative pricing models and policy reformations are enhancing affordability and availability in this category.

Transient Elastography Devices Market Size and Forecast:

Report Attribute Details

Base Year

2025

Forecast Year

2026-2035

CAGR

8.8%

Base Year Market Size (2025)

USD 326.9 million

Forecast Year Market Size (2035)

USD 759.6 million

Regional Scope

  • North America (U.S., and Canada)
  • Asia Pacific (Japan, China, India, Indonesia, Malaysia, Australia, South Korea, Rest of Asia Pacific)
  • Europe (UK, Germany, France, Italy, Spain, Russia, NORDIC, Rest of Europe)
  • Latin America (Mexico, Argentina, Brazil, Rest of Latin America)
  • Middle East and Africa (Israel, GCC North Africa, South Africa, Rest of the Middle East and Africa)
Access Detailed Forecasts & Data-Driven Insights: Request Free Sample PDF

Transient Elastography Devices Market Segmentation:

Technology Segment Analysis

Based on technology, the vibration-controlled TE (VCTE) segment is expected to hold the largest share of 52.4% in the transient elastography devices market by 2035. The segment's leadership is reflected by the strong physician preference and established reimbursement enlisting, particularly in hepatology practices. As a mainstream technology, this subtype has become the most valuable asset for liver stiffness measurement due to its proven accuracy, reproducibility, and value-based outcomes while being non-invasive, as demonstrated by numerous studies. The technology's proprietorship is further fueled by its incorporation and compliance with global medical standards and widespread availability across both hospital and outpatient settings, consolidating a steady and reliable consumer base.

Application Segment Analysis

In terms of application, the liver fibrosis assessment segment is poised to dominate the transient elastography devices market throughout the discussed timeframe. The rapid escalation in the population of patients with chronic liver diseases around the world is making this segment a priority for both service providers and dedicated MedTech pioneers. In this regard, the WHO report in April 2024 revealed that more than 1.3 million people were dying due to hepatitis each year till 2022, highlighting the need for early and accurate fibrosis detection tools. Moreover, the amplifying focus on combating risks and frequent incidences of liver-related ailments, such as NAFLD and hepatitis infections, is mandating the adoption of detecting and monitoring solutions from this sector.

End user Segment Analysis

Hospitals are leading the end-user segment due to their high patient volume, trained technician availability, and the necessity of detailed diagnostic workups. Complicated liver cases also usually need elastography to be integrated with other imaging devices and laboratory tests, which are usually done in the hospitals. Medicare reimbursement models and other national health systems' schemes for hospital-based services, combined with investments in sophisticated hospital facilities, preserve this segment's leadership.

Our in-depth analysis of the global market includes the following segments: 

Segment

Subsegment

Technology
  • Vibration-Controlled TE (VCTE)
  • Shear Wave Elastography (SWE)

Product Type
  • Portable Devices
    • Vibration-Controlled TE (VCTE)
    • Shear Wave Elastography (SWE)
  • Standalone Devices
    • Vibration-Controlled TE (VCTE)
    • Shear Wave Elastography (SWE)

Application
  • Liver Fibrosis Assessment
    • Hospitals & Clinics
    • Specialty Clinics & Diagnostic Centers
    • Ambulatory Surgical Centers
  • Cardiovascular Diseases
    • Hospitals & Clinics
    • Specialty Clinics & Diagnostic Centers
    • Ambulatory Surgical Centers
  • Oncology
    • Hospitals & Clinics
    • Specialty Clinics & Diagnostic Centers
    • Ambulatory Surgical Centers

End user
  • Hospitals & Clinics
  • Specialty Clinics & Diagnostic Centers
  • Ambulatory Surgical Centers
Vishnu Nair
Vishnu Nair
Head - Global Business Development

Customize this report to your requirements — connect with our consultant for personalized insights and options.

Transient Elastography Devices Market - Regional Analysis

North America Market Insights

North America is projected to capture the highest share of 35% in the transient elastography devices market over the assessed timeline. The region's strong emphasis on advanced healthcare infrastructure and robust adoption of non-invasive diagnostics is primarily driving this leadership. It also encompasses a continuously emphasizing patient pool, where nearly 4.5 million people are diagnosed with liver disease, with the people aged above 18, according to the Centers for Disease Control and Prevention report in January 2025. Moreover, the expansion in reimbursement coverage from Medicare and Medicaid is acting as a financial cushion for afflicted citizens, securing a greater cash inflow in this merchandise.

The U.S. is leading the transient elastography device market, and is fueled by the rising cases of nonalcoholic fatty liver disease affecting more than 38% of the people in the country, and this number has increased by 50% in the last three years, based on the American Diabetes Association data published in February 2024. Clinical adoption is strengthened by the American Association for the Study of Liver Diseases guidelines, which suggest elastography over biopsy. Further advancements in technology, such as innovations in integrating AI in devices, further enhance the accuracy and strategic deployments in point-of-care settings.

The Prevalence of Liver Diseases in the U.S. and Canada

Country

Prevalence

U.S.

4.5 million

Canada

1 in 4 individuals

Source: CDC January 2025, Liver Canada January 2025

APAC Market Insights

The Asia Pacific transient elastography devices market is predicted to be the fastest-growing landscape worldwide by the end of 2035. Heightening liver disease burden and proactive healthcare investments are the major growth drivers in this region. As per NLM data in March 2025 prevalence of NAFLD is expected to rise from 38.9%, representing a 43.2% increase over two decades. The contribution of emerging economies, such as China and India, is also adding to its clinical discoveries and commercial expansion in this category with significant investments.

China is showcasing a notable propagation in the market with its predominant captivity over raw material resources, an essential part of related tools. This can be testified by the 2024 report from the ITC, displaying this country is leading the proportion in the global piezoelectric crystal supply. Furthermore, the substantiation flow of capital from both government and private entities is also displaying a lucrative environment of business for leaders in this sector. This strategic dominance, coupled with rising domestic demand for non-invasive liver disease diagnostics, moreover places China as the leader in the global transient elastography devices market trajectory.

Europe Market Insights

The market for transient elastography devices in Europe is defined by high-quality healthcare systems, good disease awareness, and ongoing government engagement in non-invasive diagnostics. The Journal of Hepatology reported in August 2023 that liver disease accounted for 2 million deaths every year, representing 4% of all deaths. Further, the market is driven by a rising cases of non-alcoholic fatty liver disease (NAFLD) and viral hepatitis, clinical guidance favoring elastography over liver biopsies, and other factors. Technological developments such as hybrid devices that combine elastography and ultrasound, the expansion of applications beyond hepatology, and the incorporation of elastography into national screening programs are some trends.

Germany is leading the transient elastography devices market in Europe and is projected to hold the highest revenue share by 2035. The country is driven by an advanced healthcare infrastructure, high healthcare expenditure, and early adoption of advanced technologies in the healthcare sector. The report from the Federal Ministry of Health depicts that rising investments in digital diagnostics focus on non-invasive methods such as elastography. Further, the growth is driven by the rising prevalence of NAFLD, and strong reimbursement policies under the German statutory health insurance system. Further, the incorporation of AI in elastography devices into clinical workflows for enhanced accuracy and expanding screening programs for high-risk populations, driving the market growth.

Transient Elastography Devices Market Share
Get Strategic Analysis by Region Now: Request Free Sample PDF

Key Transient Elastography Devices Market Players:

    The transient elastography devices market is enriched with the contribution of top MedTech developers and manufacturers. Global giants, such as Echosens and GE Healthcare, are augmenting international expansion with advancements in AI-driven diagnostics and portable tools. On the other hand, companies, including Samsung Medison and Mindray, are focusing more on offering solutions at competitive pricing to captivate a remarkable position in the cohort of suppliers for the price-sensitive regions. Moreover, they are also strategically forming alliances to align with government-backed healthcare programs to make their patent technologies more popular and accessible to consumers.

    Below is the list of some prominent players operating in the global market:

    Company Name

    Country of Origin

    Est. 2025 Market Share

    Industry Focus & Notable Products

    Echosens

    France

    55%

    Market pioneer & leader in dedicated devices. Focused exclusively on non-invasive liver diagnostics. Its FibroScan® is the clinical gold standard for measuring liver stiffness (LSM) and controlled attenuation parameter (CAP).

    GE HealthCare

    U.S.

    10%

    Diversified imaging conglomerate. Integrates 2D Shear Wave Elastography (2D-SWE) into its high-end ultrasound systems (e.g., LOGIQ E10, Vivid E95) for a comprehensive diagnostic solution.

    Siemens Healthineers

    Germany

    8%

    Global medical technology leader. Incorporates elastography features (e.g., eSie Touch Elasticity Imaging) across its ACUSON ultrasound portfolio for radiology and point-of-care applications.

    Canon Medical Systems

    Japan

    5%

    Specialized in diagnostic imaging. Develops ultrasound systems with advanced elastography functionality (e.g., Hi-RTE) for abdominal and superficial organ assessment.

    Fujifilm Holdings

    Japan

    3%

    Leading imaging and healthcare company. Offers shear wave elastography (SWE) technology in its ARIETTA ultrasound platforms for quantitative stiffness measurement.

    Philips

    Netherlands

    xx%

    Leading health technology provider. Features elastography (e.g., ElastoPQ) on its EPIQ and Affiniti ultrasound systems for quantitative liver disease assessment.

    Mindray Medical

    China

    xx%

    Major global medical device supplier. Provides shear wave elastography (e.g., on Resona series) on its ultrasound systems, offering competitive technology at value-based price points.

    Samsung Medison (Harman)

    South Korea

    xx%

    Leading ultrasound specialist. Incorporates elastography solutions (e.g., S-Shearwave) across its product lineup (e.g., HS70, RS85) with a strong global presence.

    SuperSonic Imagine (Hologic)

    France

    xx%

    Innovator in ultrasound technology. Pioneered ultrafast imaging and ShearWave Elastography on its Aixplorer® system for quantitative tissue stiffness mapping.

    Esaote SpA

    Italy

    xx%

    Specializes in medical imaging. Integrates elastography technologies (e.g., ElaXto®) into its MyLab™ ultrasound systems for MSK and abdominal applications.

    Hitachi, Ltd.

    Japan

    xx%

    Significant player in diagnostic imaging. Its healthcare division develops ultrasound systems with advanced elastography capabilities for detailed tissue characterization.

    Shenzhen Mindray Bio-Medical

    China

    xx%

    Develops diagnostic ultrasound systems that often include elastography features, focusing on cost-effective solutions for emerging markets.

    Heal Force Bio-meditech

    China

    xx%

    Focuses on manufacturing medical equipment, including diagnostic ultrasound systems that may incorporate basic elastography features.

    Medonica Co. Ltd.

    South Korea

    xx%

    Specialized manufacturer of non-invasive liver fibroscan devices (e.g., iLivTouch), competing in the dedicated transient elastography space.

    Fukuda Denshi Co., Ltd.

    Japan

    xx%

    Prominent Japanese medical device company. Manufactures ultrasound systems with elastography functions, with a strong distribution network in Asia.

    Sonoscape Medical Corp.

    China

    xx%

    Growing Chinese manufacturer of medical imaging equipment, including ultrasound systems featuring elastography modes.

    BCF Technology Limited

    UK

    xx%

    Primarily focused on veterinary imaging. A significant niche player offering ultrasound with elastography for animal health diagnostics.

    Yokogawa Electric Corporation

    Japan

    xx%

    Primarily an industrial automation company. Its medical business unit has a limited and niche presence in diagnostic systems like elastography.

    Nihon Kohden Corporation

    Japan

    xx%

    Leader in patient monitoring and EEG. Its involvement in ultrasound and elastography is minimal and not a core business focus.

    Honda Electronics Co., Ltd.

    Japan

    xx%

    Specializes in ultrasound probes and systems. Focus is on transducer technology, with elastography being an application feature.

    Below are the areas covered for each company in the market:

    • Company Overview
    • Business Strategy
    • Key Product Offerings
    • Financial Performance
    • Key Performance Indicators
    • Risk Analysis
    • Recent Development
    • Regional Presence
    • SWOT Analysis

Recent Developments

  • In February 2025, Philips has integrated AI into the workflow and quantitative measurement functions in the EPIQ Elite and Affiniti ultrasound systems to speed up examinations and increase the clinical confidence.
  • In December 2024, Siemens Healthineers introduced ACUSON Sequoia 3.5, which is a major software and hardware update to the ACUSON Sequoia ultrasound system that uses artificial intelligence (AI), powered features for enhanced workflow and efficiency to improve the clinical performance.
  • In May 2024, Echosens introduced a new guided vibration-controlled transient elastography (VCTE) technology, available on new FibroScan systems. Further, the tool takes 4 minutes to complete a full scan and uses two visual indicators, one for liver stiffness and the other for controlled attenuation parameter, which is used to support the operator in quickly identifying the optimal measurement location.
  • Report ID: 665
  • Published Date: Sep 29, 2025
  • Report Format: PDF, PPT
  • Get detailed insights on specific segments/region
  • Inquire about report customization for your industry
  • Learn about our special pricing for startups
  • Request a demo of the report’s key findings
  • Understand the report’s forecasting methodology
  • Inquire about post-purchase support and updates
  • Ask About Company-Level Intelligence Additions

Have specific data needs or budget constraints?

customer-service Inquiry Before Buying

Frequently Asked Questions (FAQ)

In the year 2025, the industry size of transient elastography devices is estimated at USD 326.9 million.

Transient elastography devices market size is projected to grow from USD 326.9 million to USD 759.6 million, witnessing a CAGR of over 8.8% during the forecast period, between 2026 and 2035.

The north america industry is estimated to account for largest revenue share of 40.1% by end 2035.

The major players in the market are Echosens, GE HealthCare, Siemens Healthineers, Canon Medical Systems, Fujifilm Holdings, Philips, Mindray Medical, Samsung Medison (Harman), SuperSonic Imagine (Hologic), Esaote SpA, Hitachi, Ltd. and others.

Transient Elastography Devices Market Report Scope

GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

Connect with our Expert

Radhika Pawar
Radhika Pawar
Senior Research Analyst
Inquiry Before Buying Request Free Sample PDF

Copyright @ 2025 Research Nester. All Rights Reserved.

footer-bottom-logos